Object. Cushing's disease is a challenging neuroendocrine disorder. Although resection remains the primary treatment option for most patients, the disease persists if there is residual or recurrent tumor. Stereotactic radiosurgery has been used to treat patients with persistent Cushing's disease after a prior resection. The authors report on the longterm risks and benefits of radiosurgery for Cushing's disease.
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C ushing's disease is an endocrine disorder with significant systemic sequelae. Surgical removal of the pituitary adenoma remains the mainstay of treatment, and remission rates after this procedure vary from 50% to 90%. 19, 29, 30, 32 Resection can be associated with complications, including but not limited to damage to the optic apparatus, carotid artery injury, damage to CNs traversing the cavernous sinus (that is, CNs III-VI), CSF leakage, and the development of hypopituitarism. 28, 33 Moreover, adenomas associated with Cushing's disease can be difficult to completely excise because of suprasellar extension or invasion of the dura mater, cavernous sinus, or clivus. 31 Incomplete resection or recurrence of the adenoma leads to hypercortisolemia and the accompanying morbidity. Stereotactic radiosurgery has been used to treat sellar and parasellar tumors and has proven particularly valuable for treating Cushing's disease patients with recurrent or residual disease. 8, 21, 35 The Gamma Knife is particularly well suited for treating Cushing's disease because these pituitary adenomas tend to have a small volume, which facilitates delivery of a highly focused radiation dose to the tumor while sparing surrounding eloquent neurovascular structures. In the current study we detail our longterm experience with GKS in patients with residual or recurrent ACTH-secreting pituitary adenomas.
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Methods
Study Design and Patient Selection
We conducted a retrospective analysis of a prospectively maintained, institutional review board-approved database, which includes all patients treated with GKS at the University of Virginia. The database was reviewed for patients treated for Cushing's disease in the period from 1990 to 2012. Some of the patients treated prior to 2005 have already been analyzed and the results published.
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Patients were included in the present study only if they clearly demonstrated endocrine evidence of Cushing's disease according to serum cortisol, ACTH, and 24-hour UFC levels. Additionally, radiographic imaging had to be consistent with a diagnosis of pituitary adenoma. Patients were excluded from analysis if they lacked at least 12 months of clinical and radiographic follow-up. Patients were included regardless of whether GKS was used as the primary treatment or treatment for residual or recurrent disease. This study reflects updated information on all patients reached in 2012 as part of a reevaluation of our experience with GKS for Cushing's disease.
Preradiosurgical Assessment and Radiosurgical Technique
To determine preoperative endocrine function, patients with Cushing's disease undergo a preoperative laboratory evaluation within 2 months of GKS. Testing typically includes 24-hour UFC, free thyroxine, thyroidstimulating hormone, prolactin, follicle-stimulating hormone, luteinizing hormone, growth hormone, serum cortisol, adrenocorticotropic hormone, testosterone in men, estradiol (as well as menstrual history) in women, and a basic metabolic panel. Since 2010, given evidence that ketoconazole may affect GKS outcomes, we have discontinued ketoconazole 2-3 weeks in advance of GKS and resumed its administration 2-6 weeks postoperatively.
Gamma Knife surgery was performed in the fashion previously described for the University of Virginia. 36, 37 In general, while the patient is under monitored anesthesia in the operating room, a stereotactic Leksell G frame is placed. Patients are then transported to neuroradiology and undergo stereotactic MRI, which is performed as thin slice (1 mm) axial and coronal T1-weighted pre-and postcontrast sequences. Fat suppression MRI sequences through the sellar region are also performed. Treatment plans are collaboratively formulated by the treating neurosurgeon, a medical physicist, and a radiation oncologist. The Leksell Gamma Unit Model U was used until July 2001 and was then replaced by the C model (Elekta Instruments, Inc.). In 2008, the Leksell Perfexion unit replaced the C model. Kula software was used for dose planning from 1989 until June 1994 and was then replaced with Elekta's Gamma Plan software.
Data Collection and Follow-Up
The medical records of all patients were reviewed and pertinent data were gathered, including demographic information; number of previous transsphenoidal operations; number of previous craniotomies; prior external beam radiation therapy; pre-GKS serum cortisol, ACTH, and 24-hour UFC; visual field deficits; visual acuity; and pre-GKS ketoconazole usage. Radiosurgical parameters, such as lesion volume or size, number of isocenters, maximum radiation dose, and peripheral dose, were also collected. We documented whether the lesion was located in the cavernous sinus or had a suprasellar component. Additionally, if a discrete adenoma could not be visualized on stereotactic MRI and the entire sellar contents were included in the treatment volume, we recorded this information.
Endocrine deficiencies pre-GKS, including hypothyroidism, diabetes insipidus, growth hormone deficiency, and hypogonadism, were defined as either those levels requiring replacement or abnormally low laboratory values. From this information, several parameters were calculated (for example, incidence of deficiencies post-GKS). Age at GKS was defined from the date of birth to the date of GKS. Overall survival was determined using the date of death on the Social Security Death Index. Overall survival was defined from the date of GKS to the date of death.
Both clinical and radiological follow-ups were performed every 6 months for the first 2 years after GKS and on a yearly basis thereafter. Clinical follow-up was performed at the University of Virginia by the treating neurosurgeon and a neuroendocrinologist. In cases in which practical limitations prohibited the patient's return to the University of Virginia, information was gathered from the local collaborating physicians. Information included subsequent treatment with radiosurgery, radiotherapy, or pituitary surgery; serum cortisol level; 24-hour UFC values; time to endocrine remission; and remission status at last follow-up. Time to remission was defined from the date of GKS to the date of the first 24-hour UFC and morning serum cortisol levels within normal limits after GKS. 2, 27 For patients treated with ketoconazole after GKS, the drug was briefly discontinued (usually for 3 weeks) while the laboratory values were collected.
Follow-up radiographic studies were performed at the University of Virginia whenever possible. If not feasible, follow-up MR images were obtained at a hospital closer to the patient's home. At either the University of Virginia or an outside facility, follow-up MRI was performed using a consistent protocol including thin slice (1-3 mm) pre-and postcontrast MRI volume-acquisition T1-weighted sequences in the axial and coronal orientations. A neuroradiologist as well as a neurosurgeon at the University of Virginia reviewed the follow-up films. To account for the uncertainty associated with tomographic imaging, radiographic stability was defined as the target volume remaining within ± 15% of its original size.
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Adenoma growth was defined as the target volume increasing by more than 15% of its original volume, and adenoma regression represented a reduction by more than 15% of the starting volume.
Statistical Analysis
Time to endocrine remission was defined as the interval between the time of GKS and the date of endocrine normalization of serum cortisol and 24-hour UFC, with testing performed while the patient was off suppressive medications (for example, ketoconazole). All variables were presented as medians and ranges. In general, a bina-ry logistic regression analysis was performed to evaluate predictive factors pertaining to a tumor recurrence following endocrine remission. A Kaplan-Meier plot was used to determine the differences of time-to-event variables, including the time to endocrine remission or a newly developed hypopituitarism due to SRS. The time difference regarding binary variables between groups was compared using a log-rank test. A univariate analysis with a Cox proportional regression model was conducted to evaluate the contributions of parametric variables to time to event, including time to endocrine remission and new onset of SRS-induced hypopituitarism. Variables analyzed included age at SRS, patient sex, previous transsphenoidal resection, 24- hour UFC levels at the time of SRS, previous radiation therapy, administration of ketoconazole at the time of SRS (before 2010), treatment volume, dose to tumor margin, cavernous sinus involvement, and whole sellar treatment. All statistical analyses were performed using the commercially available statistical package IBM SPSS Statistics 20. All statistical tests were 2-tailed, and the significance level was set at a p value < 0.05.
Results
Patient and Treatment Attributes
Reliable and current patient information was available in 96 patients (Table 1) , 74 females (77.1%) and 22 males (22.9%). At least one transsphenoidal resection or one craniotomy had been performed in 97.9% and 3.1% of the patients, respectively. Prior radiotherapy had been performed in 6.2% of the patients. At the time of GKS, 26% of patients were receiving ketoconazole, whereas 74% had been taken off ketoconazole around the periradiosurgical period, usually 3-6 weeks before treatment.
The mean target volume was 1.8 cm 3 (range 0.2-12.4 cm 3 ; Table 2 ). The mean dose to the margin of the target volume was 22 Gy, and the mean maximal dose was 47.2 Gy. The mean number of isocenters was 4.7 (range 1-15), and the mean maximal dose to the optic apparatus was 4.6 Gy. Twenty-eight patients had GKS for a planned target volume that included the entire sella (Fig. 1) .
After GKS, the median follow-up was 48 months (range 12-209.8 months).
Endocrine Remission
The median time to remission was 16.6 months (range 1-165.7 months; Fig. 2 ). Overall endocrine remission at the last follow-up was 70% (Table 3) . Actuarial endocrine remission at 1, 2, 3, and 5 years was 34%, 54%, 72%, and 78%, respectively.
Patients on ketoconazole at the time of GKS demonstrated a median time to remission of 21.8 months (Table 3 and Fig. 3) ; however, patients off ketoconazole at the time of GKS had a median time to remission of 12.6 months. Those off ketoconazole at the time of GKS achieved a significantly more rapid remission than those on ketoconazole (p < 0.012).
Radiological Response
At the last follow-up, 70% of patients had a decrease in the size of the pituitary adenoma after radiosurgery. Twenty-eight percent had a stable adenoma after radiosurgery. After initial GKS, 2 patients (2%) demonstrated an increase in the size of the pituitary adenoma. One of these patients was retreated for an out-of-field recurrence. This patient is now radiologically stable and has endocrine remission. The second patient had adenoma growth and underwent a craniotomy to resect the progressive tumor. This patient remains on ketoconazole and has persistent Cushing's disease despite radiosurgery and repeat resection.
Endocrine Recurrence
Fifteen patients (15.6%) had an initial remission with at least one normal 24-hour UFC and morning serum cortisol level while off antisecretory medications but later had a recurrence. The median time for recurrence of Cushing's disease after an initial remission was 38 months (range 5-120.7 months). Eight of these patients underwent repeat GKS; 4 (50%) of the 8 achieved a second remission and remained in remission at the last follow-up. There was no significant difference in radiosurgical parameters or target volumes between those with a recurrence and those in remission at the last follow-up.
Hypopituitarism
New loss of pituitary function occurred in 36% of the patients. In patients in whom the whole sella was targeted, because a discrete adenoma could not be visualized on stereotactic MRI, the risk of hypopituitarism was significantly increased compared with the risk in those in whom a discrete adenoma was targeted (p = 0.010). Panhypopituitarism after GKS was not observed.
Other Complications and Treatments
Five patients (5.2%) demonstrated CN deficits following GKS (Table 4 ). Four of these 5 patients underwent repeat GKS after an initial remission followed by a recurrence of their Cushing's disease. Cranial nerves II and III were affected in 3 and 4 patients, respectively, and CN VI in 2 patients. Complete blindness did not develop in any patient after GKS. Neither did postradiosurgical stroke or radiation-induced neoplasia occur in anyone.
Eight patients with Cushing's disease refractory to GKS and medical management with ketoconazole eventually underwent bilateral adrenalectomy.
Discussion
Cushing's disease is a challenging condition for clinicians. Neurosurgeons continue to play a role in the primary treatment of this condition through resection of the pituitary adenoma. Long-term remission rates for microadenomas vary from approximately 60% to 90%. 18, 20, 32, 42 Remission rates for Cushing's disease patients with macroadenomas or invasive microadenomas are, as expected, much lower. 19 Recurrence can occur after an initial remission afforded by resection approximately 13% to 25% of the time.
29-31,42 Not surprisingly, repeat transsphenoidal surgery offers substantially lower rates of subsequent remission. Radiation therapy in Cushing's disease has a role in achieving both endocrine remission and tumor control, with rates of 0%-84% and 90% or greater, respectively.
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It is widely acknowledged that it takes longer to attain remission in patients who undergo fractionated radiation therapy than in those who undergo stereotactic radiosurgery.
11,16,26,36 Brada et al. reported that the 5-and 10-year actuarial incidence of stroke after radiation therapy ranges from 4% to 11% of patients. 5 The risk of radiationinduced neoplasia after radiotherapy is estimated as 1.3% and 1.9% over 10 and 20 years, respectively.
6 Based on our experience as well as the published radiosurgical literature, risks of ischemic stroke or neoplasia appear far lower than those afforded by fractionated radiotherapy.
36
Medical management in the form of ketoconazole, pasireotide, mitotane, or mifepristone should generally be seen as adjuvant therapy rather than a cure. 4, 7, 10, 17 Moreover, these medications require a lifetime of administration, making the approach both less practical and less cost-effective for patients. 7, 17 Failure to achieve normalized hormone levels in patients with Cushing's disease incurs substantial risks of morbidity and premature mortality. 41 Stereotactic radiosurgery has been used to treat all types of pituitary adenomas. Among patients with functioning adenomas, radiosurgery is generally performed in those with residual or recurrent adenomas and persistent hormone hypersecretion. Most radiosurgical studies of Cushing's disease feature the Gamma Knife, but some linear accelerator-and proton beam-based series have been published as well. 1, 8, 12, 13, 21, 25, [33] [34] [35] The post-SRS remission rates reported in the literature vary considerably from 0% to 100%, with most series documenting an approximately 50%-60% remission rate. 1, 8, 12, 13, 21, 25, [33] [34] [35] 38, 40 Rates of new hypopituitarism and neurological deficits respectively averaged 25% and 2.8% in published studies.
38 Further limiting the impact of the available literature is the fact that most published studies have less than 4 years of followup and small cohorts. 13, 36, 38 We did observe a higher risk of cranial neuropathy in patients undergoing repeat GKS and those with prior radiation therapy. Carefully considering prior radiation delivered to the sellar region and allowing sufficient time between initial and subsequent treatments for repair and recovery seem advisable.
Since the publication of the original reports by Landolt and colleagues, we have systematically taken patients off antisecretory medications around the time of their GKS. 23, 24 Although not seen or fully investigated in previous Cushing's studies from our center, the temporary cessation of ketoconazole clearly appeared to decrease time to remission in the present study. 21, 35 In a series of 40 patients with Cushing's disease treated via GKS, Castinetti et al. determined that patients off anticortisol medications at the time of radiosurgery were more likely to achieve remission.
8 Data in the current study, however, did not show a difference in the overall extent of remission achieved between those on and those temporarily off ketoconazole. However, they did show early remission in the patients off ketoconazole.
Cushing's disease is most frequently caused by a microadenoma, which can be difficult to detect on MRI, especially in patients who have undergone prior tumor resection. 9, 15 In patients with endocrine evidence of Cushing's disease but without a discrete adenoma on MRI, the entire sellar content was treated with radiosurgery. There was no difference in the overall rate of endocrine remission between those with a discrete adenoma on MRI and those in whom the entire sella was treated. However, loss of some pituitary function was significantly more common in the patients who had undergone radiosurgery targeting of the entire sellar volume. Inevitably, in these patients, the normal pituitary gland received at least the radiosurgical dose applied to the tumor margin. Such patients require hormonal replacement and careful endocrine assessment by a neuroendocrinologist. 37, 43 We believe that radiosurgery targeting of the entire sella (Fig.  1 ) is preferable to bilateral adrenalectomy. The latter has an approximately 8%-66% chance of leading to Nelson syndrome.
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Role of Radiosurgery in Cushing's Disease
We use GKS to treat patients with persistent or recurrent Cushing's disease after a failed resection. Remission after GKS is typically achieved in 1-2 years, and we treat patients with medications to lower cortisol production during the latency period. Although we do not have Level 1 evidence regarding the temporary cessation of cortisollowering medications around the period of radiosurgery, available evidence does point to a benefit in temporarily ceasing antisecretory medications in the patient with a functioning adenoma and undergoing radiosurgery. 
Study Limitations
The current study is retrospective, but the data were obtained from a prospectively collected database. As such, the study inherently possesses selection biases reflective of the treating physicians and referral biases of a center with a wide referral base for pituitary adenoma and radiosurgery patients. Furthermore, over the years, our radiosurgical technique has been refined, and our endocrine approach in patients has recently involved the deliberate cessation of ketoconazole around the peri-radiosurgical period. The current study represents a more homogeneous patient experience-in terms of patient selection, dose delivery, general avoidance of repeat radiosurgery except under compelling circumstances, and antisecretory medication management-than our previous experience published in 2000 and 2007. In part, the present study reflects the biases derived from our past successes and failures in radiosurgery. 21, 35 Note that some of our patients were so ill even while on ketoconazole that they underwent early adrenalectomy if they did not achieve endocrine remission within 12 months of GKS. This probably resulted in a lowering of the endocrine remission rate that may have been afforded by GKS had the patients been able to tolerate the latency period often required (that is, 12-24 months). Finally, a portion of the study patients had follow-up intervals shorter than the mean time required to attain remission. This too may have lowered the overall endocrine remission rate.
Conclusions
Gamma Knife surgery results in favorable rates of endocrine remission and tumor control in patients with Cushing's disease. Ceasing cortisol-lowering medications around the time of radiosurgery appears to lead to a more rapid remission. Delayed hypopituitarism is the most frequent complication, although it occurs in a minority of patients and is related to the volume of sellar tissue treated. These data support the use of GKS as an adjunctive treatment in patients with Cushing's disease.
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